Literature DB >> 22586314

The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development.

Eric H Rubin1, Keaven M Anderson, Christine K Gause.   

Abstract

Successful completion of the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial, reported in this issue of Cancer Discovery, is an important advance in the effort to improve clinical trial approaches to the simultaneous development of new therapeutics with matching diagnostic tests so that patients most likely to benefit from these therapies can be identified.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22586314     DOI： 10.1158/2159-8274.CD-11-0036

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  9 in total

Review 1.  Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come.

Authors:  Edward B Garon; Phillip A Abarca; Jennifer L Strunck; Danielle Nameth; Catherine Neumann; Brian Wolf; Kevin Y Kim; Caitlin Marx; Robert M Elashoff
Journal:  Crit Rev Oncog       Date:  2015

Review 2.  Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield.

Authors:  Russell M Medford; T Forcht Dagi; Robert S Rosenson; Margaret K Offermann
Journal:  Curr Atheroscler Rep       Date:  2013-05       Impact factor: 5.113

3.  Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics.

Authors:  Howard I Scher; Shelley Fuld Nasso; Eric H Rubin; Richard Simon
Journal:  Clin Cancer Res       Date:  2011-11-01       Impact factor: 12.531

4.  Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.

Authors:  Yongik Lee; Yian Wang; Michael James; Joseph H Jeong; Ming You
Journal:  Mol Carcinog       Date:  2015-06-04       Impact factor: 4.784

Review 5.  The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research.

Authors:  Donald A Berry
Journal:  Mol Oncol       Date:  2015-03-11       Impact factor: 6.603

Review 6.  Cancer biomarkers: selecting the right drug for the right patient.

Authors:  Gary J Kelloff; Caroline C Sigman
Journal:  Nat Rev Drug Discov       Date:  2012-02-10       Impact factor: 84.694

7.  Adaptive Clinical Trials: Overview of Early-Phase Designs and Challenges.

Authors:  Olga Marchenko; Valerii Fedorov; J Jack Lee; Christy Nolan; José Pinheiro
Journal:  Ther Innov Regul Sci       Date:  2013-11-26       Impact factor: 1.778

Review 8.  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Authors:  David D Bowtell; Steffen Böhm; Ahmed A Ahmed; Paul-Joseph Aspuria; Robert C Bast; Valerie Beral; Jonathan S Berek; Michael J Birrer; Sarah Blagden; Michael A Bookman; James D Brenton; Katherine B Chiappinelli; Filipe Correia Martins; George Coukos; Ronny Drapkin; Richard Edmondson; Christina Fotopoulou; Hani Gabra; Jérôme Galon; Charlie Gourley; Valerie Heong; David G Huntsman; Marcin Iwanicki; Beth Y Karlan; Allyson Kaye; Ernst Lengyel; Douglas A Levine; Karen H Lu; Iain A McNeish; Usha Menon; Steven A Narod; Brad H Nelson; Kenneth P Nephew; Paul Pharoah; Daniel J Powell; Pilar Ramos; Iris L Romero; Clare L Scott; Anil K Sood; Euan A Stronach; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

9.  Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor.

Authors:  Shengwen Calvin Li; Lisa May Ling Tachiki; Mustafa H Kabeer; Brent A Dethlefs; Michael J Anthony; William G Loudon
Journal:  Cancer Cell Int       Date:  2014-11-12       Impact factor: 5.722
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.